JPH0561272B2 - - Google Patents

Info

Publication number
JPH0561272B2
JPH0561272B2 JP63172964A JP17296488A JPH0561272B2 JP H0561272 B2 JPH0561272 B2 JP H0561272B2 JP 63172964 A JP63172964 A JP 63172964A JP 17296488 A JP17296488 A JP 17296488A JP H0561272 B2 JPH0561272 B2 JP H0561272B2
Authority
JP
Japan
Prior art keywords
group
compound
oxybutenolide
conjugated
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP63172964A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0222271A (ja
Inventor
Hironobu Tamai
Masahiro Torihara
Yoichi Kido
Joji Yamahara
Masayoshi Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuraray Co Ltd
Original Assignee
Kuraray Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuraray Co Ltd filed Critical Kuraray Co Ltd
Priority to JP63172964A priority Critical patent/JPH0222271A/ja
Priority to US07/369,007 priority patent/US4950818A/en
Priority to DE89112692T priority patent/DE68911776T2/de
Priority to EP89112692A priority patent/EP0350878B1/en
Priority to ES89112692T priority patent/ES2061811T3/es
Publication of JPH0222271A publication Critical patent/JPH0222271A/ja
Publication of JPH0561272B2 publication Critical patent/JPH0561272B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP63172964A 1988-07-11 1988-07-11 共役γ−オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤 Granted JPH0222271A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP63172964A JPH0222271A (ja) 1988-07-11 1988-07-11 共役γ−オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤
US07/369,007 US4950818A (en) 1988-07-11 1989-06-21 Method for treating ulcer
DE89112692T DE68911776T2 (de) 1988-07-11 1989-07-11 Konjugierte Oxybutenolide zur Behandlung von Ulcera.
EP89112692A EP0350878B1 (en) 1988-07-11 1989-07-11 Conjugated gamma-oxybutenolide compounds for treating ulcer
ES89112692T ES2061811T3 (es) 1988-07-11 1989-07-11 Uso de compuestos de gamma-oxibutenolido conjugados para tratar ulcera.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63172964A JPH0222271A (ja) 1988-07-11 1988-07-11 共役γ−オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤

Publications (2)

Publication Number Publication Date
JPH0222271A JPH0222271A (ja) 1990-01-25
JPH0561272B2 true JPH0561272B2 (en, 2012) 1993-09-06

Family

ID=15951626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63172964A Granted JPH0222271A (ja) 1988-07-11 1988-07-11 共役γ−オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤

Country Status (5)

Country Link
US (1) US4950818A (en, 2012)
EP (1) EP0350878B1 (en, 2012)
JP (1) JPH0222271A (en, 2012)
DE (1) DE68911776T2 (en, 2012)
ES (1) ES2061811T3 (en, 2012)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171863A (en) * 1987-06-08 1992-12-15 Allergan, Inc. Intermediates for preparing 4-substituted 2-5(H)-furanones as anti-inflammatory agents
US5134128A (en) * 1987-06-08 1992-07-28 Allergan, Inc. Anti-inflammatory furanones
US5045564A (en) * 1988-12-07 1991-09-03 Allergan, Inc. Anti-inflammatory 2-furanones
JP2790335B2 (ja) * 1989-09-20 1998-08-27 株式会社クラレ 共役γ―オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤
US5258400A (en) * 1989-11-20 1993-11-02 Allergan, Inc. Anti-inflammatory furanone compounds
US5112853A (en) * 1989-11-20 1992-05-12 Allergan, Inc. Anti-inflammatory furanone compounds
US5225571A (en) * 1991-04-30 1993-07-06 Allergan, Inc. Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents
US5183906A (en) * 1991-04-30 1993-02-02 Allergan, Inc. 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents
US5169963A (en) * 1991-08-30 1992-12-08 Allergan, Inc. Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5171864A (en) * 1991-08-30 1992-12-15 Allergan, Inc. Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5268387A (en) * 1992-04-24 1993-12-07 Allergan, Inc. Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss
CN111233843B (zh) * 2020-01-20 2021-07-02 中山大学 一种γ-丁烯酸内酯类衍生物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5916884A (ja) * 1982-07-19 1984-01-28 Fujisawa Pharmaceut Co Ltd 新規フラン化合物
JPS6465877A (en) * 1987-09-05 1989-03-13 Fujitsu Ltd Method of mounting optical semiconductor device

Also Published As

Publication number Publication date
EP0350878B1 (en) 1993-12-29
US4950818A (en) 1990-08-21
EP0350878A3 (en) 1991-10-09
JPH0222271A (ja) 1990-01-25
ES2061811T3 (es) 1994-12-16
DE68911776D1 (de) 1994-02-10
EP0350878A2 (en) 1990-01-17
DE68911776T2 (de) 1994-04-14

Similar Documents

Publication Publication Date Title
EP0918514B1 (en) Triaryl methane compounds for the treatment of cancer, actinic keratosis and kaposi's sarcoma
JP3499905B2 (ja) グアニジンアルキル−１，１−ビスホスホン酸誘導体、その製法およびその使用
JP3122792B2 (ja) 新規な活性化合物
JPH0561272B2 (en, 2012)
JPS6033818B2 (ja) 新ナフタレン誘導体の製法
JP4384495B2 (ja) 固体のベンズアゼピン化合物の塩および医薬化合物の調製におけるそれらの使用
EP0703915B1 (en) Xamoneline tartrate
CA2433190C (en) Amlodipine hemimaleate
JPH0129766B2 (en, 2012)
JP2790335B2 (ja) 共役γ―オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤
JPS63239248A (ja) 抗脂血剤
EP0058009A1 (en) Novel benzanilide derivatives and pharmaceutical compositions containing them
US4564685A (en) Diphenylmethane compounds
JPH11500754A (ja) 新規化合物および多発性硬化症の処置法
US4156009A (en) Diazepine derivatives
RU2242472C1 (ru) Этаноляты n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина, способ их получения, фармацевтическая композиция на основе этих соединений и способ получения мезилатной соли n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина
JPH0560465B2 (en, 2012)
JP3139690B2 (ja) 発癌予防剤
EP0151052A2 (fr) Aminoéthylimidazole, composition pharmaceutique en contenant et procédé de préparation
US4380668A (en) Decaprenylamine derivatives
US4431811A (en) Decaprenylamine derivatives
BG60536B2 (bg) Производни на тиазолидинона,фармацевтични състави които ги съдържат и метод за получаването им
JPS625417B2 (en, 2012)
JPS6248673B2 (en, 2012)
JPH0551317A (ja) 脳機能改善薬

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees